• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by PMV Pharmaceuticals Inc.

    9/10/25 6:50:45 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PMVP alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001055951
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    PMV Pharmaceuticals, Inc.
    SEC File Number
    001-39539
    Address of Issuer
    400 Alexander Park Drive
    Suite 301
    Princeton
    NEW JERSEY
    08540
    Phone
    609-642-6670
    Name of Person for Whose Account the Securities are To Be Sold
    OrbiMed Private Investments V, LP
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Shareholder

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    Themis Trading LLC
    10 Townsquare
    Chatham � NJ � 07928
    22836543653846.405299086409/10/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock09/29/2020Initial Public OfferingIssuerCheckbox not checked228365409/29/2020Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    OrbiMed Capital GP V LLC is the general partner of OrbiMed Private Investments V, LP. OrbiMed Advisors LLC is the managing member of OrbiMed Capital GP V LLC.
    Date of Notice
    09/10/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Douglas Coon, Chief Compliance Officer, OrbiMed Advisors LLC, managing member of the general partner of OrbiMed Private Investments V, LP

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $PMVP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMVP

    DatePrice TargetRatingAnalyst
    11/8/2024$6.00Perform → Outperform
    Oppenheimer
    5/13/2024$6.00Buy
    Craig Hallum
    4/12/2024$5.00Buy
    Jefferies
    12/27/2023$7.00Buy
    Ladenburg Thalmann
    3/2/2022$30.00Perform → Outperform
    Oppenheimer
    3/2/2022Perform → Outperform
    Oppenheimer
    9/22/2021$35.00 → $43.00Neutral → Buy
    Goldman Sachs
    8/19/2021Perform
    Oppenheimer
    More analyst ratings

    $PMVP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Orbimed Advisors Llc sold $900,000 worth of shares (500,000 units at $1.80) (SEC Form 4)

    4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)

    9/12/25 5:09:08 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel & COO Ticktin Robert sold $24,651 worth of shares (23,151 units at $1.06), decreasing direct ownership by 19% to 98,695 units (SEC Form 4)

    4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)

    7/3/25 7:51:53 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Jalota Deepika sold $35,198 worth of shares (33,065 units at $1.06), decreasing direct ownership by 27% to 89,959 units (SEC Form 4)

    4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)

    7/3/25 7:50:11 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    SEC Filings

    View All

    SEC Form 144 filed by PMV Pharmaceuticals Inc.

    144 - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    9/10/25 6:50:45 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Regulation FD Disclosure

    8-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)

    9/10/25 12:04:39 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by PMV Pharmaceuticals Inc.

    SCHEDULE 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    8/14/25 4:02:29 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

    PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma33% overall response rate (ORR) observed among 97 evaluable patients across all cohorts with a median duration of response of 6.2 months43% ORR observed among 44 evaluable patients in ovarian cancer cohort with a median duration of response of 7.6 monthsRezatapopt New Drug Application submission for platinum resistant/refractory ovarian cancer planned in first quarter of 2027Company to host investor webinar at 8:00 AM ET today to review Phase 2 interim clinical data PRINCETON

    9/10/25 7:00:00 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

    PMV will host an investor webinar on Wednesday, September 10, 2025 at 8:00 AM ET to review Phase 2 PYNNACLE clinical trial interim analysis   Interim analysis will include data for approximately 65 patients with at least 18 weeks of follow-up Cash, cash equivalents, and marketable securities of $148.3 million as of June 30, 2025, providing expected cash runway to end of 2026 PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the second quarter ended June

    8/7/25 8:42:03 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

    PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings. TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA Date: Tuesday, May 27, 2025Time: 11:30 AM EDT Jefferies Global Healthcare Conference Date: Thursday, June 5, 2025Time: 3:45 PM E

    5/23/25 4:05:00 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    PMV Pharmaceuticals upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded PMV Pharmaceuticals from Perform to Outperform and set a new price target of $6.00

    11/8/24 7:58:24 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Hallum initiated coverage on PMV Pharmaceuticals with a new price target

    Craig Hallum initiated coverage of PMV Pharmaceuticals with a rating of Buy and set a new price target of $6.00

    5/13/24 8:31:58 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on PMV Pharmaceuticals with a new price target

    Jefferies initiated coverage of PMV Pharmaceuticals with a rating of Buy and set a new price target of $5.00

    4/12/24 7:35:19 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    Leadership Updates

    Live Leadership Updates

    View All

    PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors

    CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced the appointment of Carol Gallagher, Pharm.D., to its Board of Directors. Dr. Gallagher brings more than 30 years of biotech leadership and expertise in drug development and commercialization. She replaces Thilo Schroeder, Ph.D., who is stepping down from the Board. The Board changes are effective immediately. "We are thrilled to welcome Carol to our Board. She is a recognized industry leader with a stellar track record of creating value. Her capabilities in

    11/4/22 8:00:00 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

    Continued progress with Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors that have a p53 Y220C mutationStrong cash, cash equivalents and marketable securities of $314.1 million as of December 31, 2021 CRANBURY, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided corporate highlights. "We expect that 2022 will be another pr

    3/1/22 7:15:00 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharma Announces Changes to its Board of Directors

    CRANBURY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced the appointment of Kirsten Flowers to its Board of Directors. Concurrent with the appointment of Ms. Flowers, Peter Thompson, M.D. will resign from PMV's Board. "Peter has been an invaluable member of the Board during a period of substantial growth and key successes, including completion of our IPO as well as entry of our lead candidate, PC14586, into the clinic," said David Mack, Ph.D., President and Chief Executive Officer of PMV. "On behalf o

    1/6/22 8:00:00 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PMV Pharmaceuticals Inc.

    SC 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    12/12/24 12:29:41 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PMV Pharmaceuticals Inc.

    SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    11/14/24 12:24:48 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PMV Pharmaceuticals Inc.

    SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    7/8/24 4:32:39 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care